The Life Sciences Report
Notable Quotes
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk High: | ||
Experts Commenting on This Company
|
Astex Pharmaceuticals Inc.TICKER: ASTX:NASDAQAstex Pharmaceuticals Inc. is dedicated to the discovery and development of small-molecule therapeutics with a focus on oncology. The company is developing a proprietary pipeline of novel therapies and is creating derisked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen (decitabine) for injection and receives significant royalties on global sales. |
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Jason Zhang, Edison Investment Research (5/7/13) "A more than 70% appreciation in the share price over the past two months suggests the market is recognizing the potential value in Astex Pharmaceuticals Inc.'s internal pipeline, particularly SGI-110. . .we consider there to be an attractive investment case with multiple upside catalysts. . .we value Astex at $678M, equivalent to $7.25/share. . .SGI-110, a second-generation hypomethylating agent (HMA), is now the clear focus of investor interest—the drug has a proven mechanism of action and potential advantages over first-generation HMAs. . .we see significant potential value increases as SGI-110 and AT13387 advance into later stages of development in the next 12-18 months."
Michael King, JMP Securities (4/30/13) "Enrollment in Astex Pharmaceuticals Inc.'s SGI-110 phase 2 expansion cohorts is half complete, while updates from phase 1 duration of response are anticipated at the European Hematology Association meeting as the company reports Q1/13 earnings. We reiterate our Market Outperform rating and $8 price target based on discounted cash flow, sum-of-the-parts and comparable company valuation methodologies."
Michael King, JMP Securities (4/8/13) "We are reiterating our Market Outperform rating and $8 price target on Astex Pharmaceuticals Inc. . .we are increasingly encouraged by clinical prospects for SGI-110. . .and in our view, investors do not afford appropriate value to the company's pipeline of partnered products, such as AZD5363. . .AZD5363 is among the leading AKT inhibitors, a class of compound that has major potential in a variety of solid tumors. Investors should view recent data as an encouraging sign of Astex's drug discovery potential, and should begin to derisk the future royalty streams from the company's partnered programs."
Michael King, JMP Securities (4/2/13) "We are initiating coverage on Astex Pharmaceuticals Inc. with a Market Outperform rating. . .even with the threat of generic entrants in the U.S. beginning in Q2/13, we believe that the 10-year market exclusivity of Dacogen in the EU, together with the clinical and commercial potential of its development candidates SGI-110 and AT13387, will create appreciable upside to the company's current valuation."
Robert Wasserman, Dawson James Securities (3/15/13) "Astex Pharmaceuticals Inc. shares have performed very well over the past 12 months, reflecting the company's strong cash position, ($138M as of Dec. 31, 2012), increased revenues from Dacogen in 2012, expanding pipeline (multiple phase 2 trials and entering phase 3 as early as this year) and strong big pharma partnerships. . .recent pipeline advancements and anticipated near-term events are expected to keep earlier share price momentum going, and thus we are reiterating our Market Outperform rating."
